Trials / Recruiting
RecruitingNCT05731258
Observational of Adjuvant Treatment of Breast Cancer With Liposomal Doxorubicin Regimen
Clinical Observational Study of Postoperative Adjuvant Treatment of Breast Cancer With Liposomal Doxorubicin Regimen
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 150 (estimated)
- Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this observational study aims to observe and evaluate the efficacy and safety of a liposomal doxorubicin containing regimen in the postoperative adjuvant treatment of breast cancer patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Liposomal doxorubicin containing regimen | Liposomal doxorubicin hydrochloride (PLD) 30-40mg/m2 D1 + other drugs (decided by investigators); All patients were treated with 4 cycles. |
Timeline
- Start date
- 2022-05-01
- Primary completion
- 2027-10-01
- Completion
- 2032-10-01
- First posted
- 2023-02-16
- Last updated
- 2023-02-16
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05731258. Inclusion in this directory is not an endorsement.